Nike and NBA Introduce New Statement Edition Uniform, First On-Court Hooded Jacket and the First NBA Connected Jersey, the Future of Fan Apparel
Ushering in a radical evolution of the fan experience, NIKE, Inc. (NYSE:NKE) and the NBA today unveiled three new innovations: the Nike NBA Connected Jersey, the first NBA jersey that gives the wearer an all-access pass into the world of their favorite team and players; Statement Edition uniforms; and the Nike Therma Flex Showtime Warm-up Jacket, the first hooded jacket to be worn on the court during gametime. The official announcements took place at an event in Los Angeles attended by players from all 30 NBA teams.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170915005965/en/
Using New NikeConnect Technology, Retail Jerseys Will Unlock Exclusive Experiences and Customized Content for Fans' Favorite Teams and Players (Photo: Business Wire)
“When you think about basketball, you think of Nike and the NBA,” said Mark Parker, Chairman, CEO and President of NIKE, Inc. “After helping fuel the sport’s impact for years, we are thrilled to now be able to push the boundaries of what’s possible directly with the NBA. From modernizing the look of the game to revolutionizing how fans can be a part of it, we can’t wait for the season to start.”
“Our Nike uniforms set a new standard for connecting our most passionate fans with their favorite NBA teams and players,” said Adam Silver, NBA Commissioner. “Nike has once again taken the game of basketball to a new level, this time with one of the most advanced jerseys in sports.”
Using new NikeConnect technology, each adult-sized Nike NBA Connected Jersey will have an embedded NFC (near field communication) chip that will launch real-time team and player content such as pregame arrival footage, highlight packages and top players’ favorite music playlists – all on the jersey owner’s mobile device. Throughout the season, a wealth of exclusive offers and experiences will bring fans closer to the game they love.
To unlock it all, fans will download the NikeConnect app and tap the jersey with their smartphone. These jerseys become available online globally on Sept. 29, rewarding the game’s fans with a revolutionary experience that creates a new point of connection between fans and the game.
“In our new connected era, Nike will lead with products that build a relationship with our consumers,” said Trevor Edwards, President, Nike Brand. “With NikeConnect, we deliver to basketball fans everywhere the personal and premium experiences we know they love.”
Nike and the NBA also unveiled the third of four core team uniforms – the Statement Edition, inspired by teams’ desire to make a bold statement the moment they step on the court. Nike’s designers worked with the teams and the brand’s roster of athletes to create new and updated uniforms for this third edition.
The Statement Edition uniform follows the earlier unveiling of the Association and Icon Edition uniforms. As previously announced, the home teams will determine which uniforms to wear at their games. The fourth team edition will be released later this year.
In addition to the new uniforms, Nike and the NBA debuted the Nike Therma Flex Showtime Warm-up Jacket, the first on-court warm-up jacket with a performance hood. Celebrating the style of the game, Nike designers refreshed a beloved apparel staple into a new performance product for athletes on and off the court.
The jacket, created with new Nike Therma Flex fabric, helps athletes maintain the right body temperature during pregame warm-ups and downtime during a game – a critical element for peak performance. Developed with input from top NBA athletes, the reimagined hood allows for optimal vision, hearing and warmth, delivering a greater intersection between performance and style – a key request from NBA athletes.
The Nike NBA Connected Jersey is available exclusively online starting Sept. 29, and the Nike NBA uniforms and Nike Therma Flex Showtime Warm-up Jacket will debut on court on Sept. 30, the start of the NBA preseason. All Statement Edition jerseys will be available at retail on Nov. 20, and will begin being worn on-court on Nov. 25.
About the NBA
The NBA is a global sports and media business built around three professional sports leagues: the National Basketball Association, the Women’s National Basketball Association and the NBA G League. The league has established a major international presence with games and programming in 215 countries and territories in 49 languages, and NBA merchandise for sale in more than 125,000 stores in 100 countries on 6 continents. NBA rosters at the start of the 2016-2017 season featured a record 113 international players from 41 countries and territories. NBA Digital’s assets include NBA TV, NBA.com, NBA App and NBA LEAGUE PASS. The NBA has created one of the largest social media communities in the world, with more than 1.3 billion likes and followers globally across all league, team and player platforms. Through NBA Cares, the league addresses important social issues by working with internationally recognized youth-serving organizations that support education, youth and family development and health-related causes.
About NIKE, Inc.
NIKE, Inc., based near Beaverton, Ore., is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Wholly-owned NIKE, Inc. subsidiary brands include Converse, which designs, markets and distributes athletic lifestyle footwear, apparel and accessories; and Hurley, which designs, markets and distributes surf and youth lifestyle footwear, apparel and accessories. For more information, NIKE, Inc.’s earnings releases and other financial information are available at http://investors.nike.com. Individuals can also visit http://news.nike.com/ and follow @Nike.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170915005965/en/
Contact information
Nike Media Contact:
Nike Media
Relations, 212-367-4447
Media.Relations@nike.com
or
NBA
Media Contact:
Amanda Thorn, 914-282-0257
athorn@nba.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom